Imbruvica lassoes CLL indication

The FDA has expanded the indication for Johnson & Johnson and Pharmacyclics' Imbruvica to include chronic lymphocytic leukemia patients who have a chromosome 17 deletion which is associated with a poor response to standard CLL treatments.

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February. The FDA approved Imbruvica for the rare, aggressive cancer mantle cell lymphoma in November 2013.

You must be a registered member of MMM to post a comment.